Five things for pharma marketers to know: Friday, June 23, 2017

Five things for pharma marketers to know: Friday, June 23, 2017

Novartis drug prevents heart attacks and strokes, per trial; Senate lawmakers unveil healthcare bill; Pfizer receives CRL for Epogen biosimilar

Five things for pharma marketers to know: Thursday, June 22, 2017

Five things for pharma marketers to know: Thursday, June 22, 2017

The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement

The FDA attempts to understand how disclosures affect drug ads

The FDA attempts to understand how disclosures affect drug ads

The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.

Five things for pharma marketers to know: Wednesday, June 21, 2017

Five things for pharma marketers to know: Wednesday, June 21, 2017

Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis' eye drug requires less frequent injections

How Zicam made the most of TV's cold season

How Zicam made the most of TV's cold season

How Zicam proved that there is a better, more data-driven approach to buying and measuring TV advertising..

Allergan reaches the masses via unbranded Botox Facebook page

Allergan reaches the masses via unbranded Botox Facebook page

In only four months, Allergan's unbranded Facebook page for Botox has garnered 32 million brand impressions and 12,000 likes.

Area 23's Healthcare Agency of the Year win was four years in the making

Area 23's Healthcare Agency of the Year win was four years in the making

The FCB Health network won big this year with several campaigns, including work featuring a bra that detects breast cancer and an awareness campaign for human trafficking.

Five things for pharma marketers to know: Tuesday, June 20, 2017

Five things for pharma marketers to know: Tuesday, June 20, 2017

Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise

Drugmakers must take the lead on opioid epidemic comms, say experts

Drugmakers must take the lead on opioid epidemic comms, say experts

Drugmakers are increasingly facing blame from regulators, lawmakers, and the public as the list of lawsuits and investigations at the state and local levels grows.

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.